Shots:

• Everest to get the rights to develop & commercialize Abs resulting from the collaboration. AbCellera to receive research payments and is eligible to receive clinical and commercial milestones along with royalties on net sales of products
• The collaboration will accelerate Everest’s portfolio to discover novel medicines for up to 10 targets across multiple indications by utilizing AbCellera’s AI technology
• Everest gets a benefit from an operating system that helps to supports many antibody modalities to unlock new target classes and open new disease areas to therapeutic access

Click here  | Ref: Businesswire | Image: AbCellera